FITC荧光Anti-HLA-DR抗体[LN3] (ab1182)
Key features and details
- FITC Mouse monoclonal [LN3] to HLA-DR
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG2b
概述
-
产品名称
FITC荧光Anti-HLA-DR抗体[LN3]
参阅全部 HLA-DR 一抗 -
描述
FITC荧光小鼠单克隆抗体[LN3] to HLA-DR -
宿主
Mouse -
偶联物
FITC. Ex: 493nm, Em: 528nm -
特异性
This antibody recognizes Human class II histocompatibility antigen. -
经测试应用
适用于: Flow Cytmore details -
种属反应性
与反应: Human -
免疫原
Tissue, cells or virus. Activated human peripheral blood mononuclear cells
-
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C. -
存储溶液
Preservative: 0.1% Sodium azide
Constituent: 0.5% BSA -
Concentration information loading...
-
纯度
Immunogen affinity purified -
克隆
单克隆 -
克隆编号
LN3 -
骨髓瘤
unknown -
同种型
IgG2b -
轻链类型
unknown -
研究领域
相关产品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
应用
应用 | Ab评论 | 说明 |
---|---|---|
Flow Cyt |
Use 1µl for 106 cells.
Characterization of leukemias in human lysed whole peripheral blood or mononuclear cells separated by density gradient. Identification of HLA DR tumors. HLA-DR (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
ab91368 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.
|
说明 |
---|
Flow Cyt
Use 1µl for 106 cells. Characterization of leukemias in human lysed whole peripheral blood or mononuclear cells separated by density gradient. Identification of HLA DR tumors. HLA-DR (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
ab91368 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.
|
靶标
-
功能
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. -
序列相似性
Belongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain. -
翻译后修饰
Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective. -
细胞定位
Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. - Information by UniProt
-
数据库链接
- Entrez Gene: 3122 Human
- Omim: 142860 Human
- SwissProt: P01903 Human
- Unigene: 520048 Human
-
别名
- DASS-397D15.1 antibody
- DR alpha chain antibody
- DR alpha chain precursor antibody
see all
图片
-
Overlay histogram showing peripheral blood lymphocytes stained with ab1182 (red line). The cells incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab1182, 0.01 µg/1x106 cells) for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b FITC (0.1 µg/1x106 cells ) for 30 min at 22°C. Acquisition of >5,000 events was performed.
数据表及文件
-
SDS download
-
Datasheet download
文献 (8)
ab1182 被引用在 8 文献中.
- Li GQ et al. MicroRNA-21 from bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. Ther Adv Chronic Dis 12:20406223211007369 (2021). PubMed: 33995992
- Meng Q & Qiu B Exosomal MicroRNA-320a Derived From Mesenchymal Stem Cells Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Activation by Suppressing CXCL9 Expression. Front Physiol 11:441 (2020). PubMed: 32528301
- Ding F et al. microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer. Stem Cell Res Ther 11:455 (2020). PubMed: 33109266
- Savic LJ et al. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy? Radiology 296:575-583 (2020). PubMed: 32633675
- Jiang Y et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miR-25 Regulates the Ubiquitination and Degradation of Runx2 by SMURF1 to Promote Fracture Healing in Mice. Front Med (Lausanne) 7:577578 (2020). PubMed: 33425934
- Shi Q et al. Differentiation of human umbilical cord Wharton's jelly-derived mesenchymal stem cells into endometrial cells. Stem Cell Res Ther 8:246 (2017). PubMed: 29096715
- Andrade RE et al. Distribution and immunophenotype of the inflammatory cell population in the benign lymphoepithelial lesion (Mikulicz's disease). Hum Pathol 19:932-41 (1988). PubMed: 3402982
- Azumi N et al. Antigenic phenotype of Langerhans cell histiocytosis: an immunohistochemical study demonstrating the value of LN-2, LN-3, and vimentin. Hum Pathol 19:1376-82 (1988). PubMed: 2973428